» Articles » PMID: 37059571

Incidence and Prevalence of Multiple Sclerosis in China and Other Asian Countries

Overview
Specialty Neurology
Date 2023 Apr 14
PMID 37059571
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence of multiple sclerosis (MS) in Asian countries is thought to be lower than in Western countries, with Asian populations presenting 80% less risk of MS than white populations. Incidence and prevalence rates in Asian countries are therefore not well defined and their association with rates in neighboring countries, as well as with ethnic, environmental, and socioeconomic factors, are not well understood. We performed a comprehensive literature review of epidemiological data from China and neighbouring countries to study the frequency of the disease, focusing on prevalence, and the progression over time and the influence of sex-related, environmental, dietary, and sociocultural factors. Prevalence rates in China range between 0.88 cases/100,000 population in 1986 and 5.2 cases/100,000 population in 2013, with a non-significant upwards trend (p = .08). The increase observed in Japan, where figures ranged between 8.1 and 18.6 cases/100,000 population was highly significant (p < .001). Prevalence rates in countries with predominantly white populations are considerably higher and have increased over time, reaching 115 cases/100,000 population in 2015 (r = 0.79, p < .0001). In conclusion, the prevalence of MS in China appears to have risen in recent years, although Asian populations (including Chinese and Japanese populations, among others) appear to present less risk than other populations. Within Asia, geographical latitude appears not to be a determining factor for developing MS.

Citing Articles

Clinical and epidemiological characteristics of multiple sclerosis in the southern region of the Republic of Azerbaijan.

Aliyev R, Mehtiyeva S, Shiraliyeva R Pak J Med Sci. 2025; 41(2):437-442.

PMID: 39926687 PMC: 11803787. DOI: 10.12669/pjms.41.2.11373.


Comparison of the effects of nursing and peer education on quality of life and resilience in patients with multiple sclerosis: A randomized clinical trial.

Siahvashi M, Shamsizadeh M, Tapak L, Ghiasian M, Azizi A Heliyon. 2024; 10(20):e39453.

PMID: 39502222 PMC: 11535978. DOI: 10.1016/j.heliyon.2024.e39453.


Epidemiology and distribution of 207 rare diseases in China: A systematic literature review.

Wang Y, Liu Y, Du G, Liu Y, Zeng Y Intractable Rare Dis Res. 2024; 13(2):73-88.

PMID: 38836174 PMC: 11145401. DOI: 10.5582/irdr.2024.01001.


Multiple sclerosis and COVID-19: a northern China survey.

Guo Q, Wang T, Huang Y, Wang F, Hao P, Le Fang Neurol Sci. 2024; 45(8):3563-3571.

PMID: 38722503 PMC: 11254961. DOI: 10.1007/s10072-024-07578-6.


Safety of teriflunomide in Chinese adult patients with relapsing multiple sclerosis: A phase IV, 24-week multicenter study.

Quan C, Zhou H, Yang H, Jiao Z, Zhang M, Zhang B Chin Med J (Engl). 2024; 138(4):452-458.

PMID: 38311806 PMC: 11845184. DOI: 10.1097/CM9.0000000000002990.